Filter By Category
Archives
Share on -
ANSELAMIMAB
Generic Name: ANSELAMIMAB
ABSTRACT -
Anselamimab is a chimeric monoclonal antibody that binds misfolded light-chain amyloid deposits.
It has been developed for AL amyloidosis with the goal of promoting clearance of amyloid deposits from affected organs.
It remains investigational and should not be used outside authorized trials or access programs.
DOSAGE -
- Dosage should be determined only by a qualified specialist.
- Clinical protocols have used intravenous dosing under close monitoring for AL amyloidosis.
- Dose, infusion duration, premedication, and continuation depend on the trial protocol and organ status.
- No approved routine dose is established.
SIDE EFFECTS–
- Possible side effects may include:
- Infusion-related reaction
- Fatigue
- Nausea
- Headache
- Peripheral edema
- Hypotension
- Fever or chills
- Hypersensitivity
ALLRGIC REACTIONS–
- Hypersensitivity to the active biologic or formulation excipients is possible.
- Symptoms may include rash, urticaria, pruritus, facial swelling, bronchospasm, fever, chills, hypotension, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Concurrent plasma-cell-directed chemotherapy may increase overlapping toxicity.
- Other biologics may increase immune-related adverse events.
- Carefully review anticoagulants and cardiac medicines in amyloidosis patients.
PREAUTIONS–
- Evaluate cardiac, renal, hepatic, and autonomic involvement before treatment.
- Monitor for infusion reactions and volume sensitivity.
- Use caution in advanced cardiac amyloidosis.
- Pregnancy and lactation safety are not established.
WARNINGS –
- AL amyloidosis can involve fragile cardiac and renal function.
- Serious infusion reactions and clinical deterioration require urgent evaluation.
- Use only in specialist centers.
Share on -
. Developed by